GlassScriptPhysician profile
Allyson Fortis
NPI 1174110092
$441.91
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $419 · 2023: $22.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $103.01 | 2022 | |
| Daiichi Sankyo INC. | $66.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $57.69 | 2022 | |
| Genzyme Corporation | $38.58 | 2022 | |
| Gilead Sciences, INC. | $22.68 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.40 | 2022 | |
| Lilly USA, LLC | $21.23 | 2022 | |
| Janssen Biotech, INC. | $17.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.81 | 2022 | |
| G1 Therapeutics, INC. | $17.44 | 2022 | |
| Amgen INC. | $17.26 | 2022 | |
| Morphosys, US INC. | $17.01 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $11.93 | 2022 | |
| Seagen INC. | $11.84 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Fortis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.